Financial Data and Key Metrics Changes - Copper production in 2025 reached 52.4 thousand tons, down 8% year-over-year due to processing stockpiles with higher precious metal content [5] - Silver production was 15.6 million ounces, a 1% increase from 15.5 million ounces in the previous year [6] - Gold production decreased by 18% year-on-year to 121,000 ounces, primarily due to lower output at Orcopampa and Tambomayo [6] - EBITDA from direct operations for 2025 was $112 million, an 88% increase from $431.5 million in 2024 [6] - Net income for 2025 was $830 million, compared to $460 million in 2024, including $157.3 million from the sale of Chaupiloma [6] - The company ended the year with a cash position of $530 million and total debt of $710 million, resulting in a leverage ratio of 0.22 times [7] Business Line Data and Key Metrics Changes - San Gabriel project reached 99% overall progress, with CapEx in Q4 2025 amounting to $153 million, mainly for the processing plant construction [7] - The company anticipates stable copper and silver production at El Brocal and Uchucchacua Yumpag, maintaining consistent output levels [8] - For 2025, total CapEx is expected to be between $385 million and $415 million, with sustaining CapEx focused on mine development and readiness works at San Gabriel [8] Market Data and Key Metrics Changes - The company expects gold production guidance for 2026 to be between 48,000 and 55,000 ounces, with pending milestones to achieve full potential [10] - The cash position increased in Q4 2025, driven by net cash inflows from operating activities [9] Company Strategy and Development Direction - San Gabriel is expected to become the main gold-producing asset, playing a key role in the long-term growth strategy [8] - The company aims to step up exploration investment to reinforce reserves and resources while enhancing efficiency through progressive closures [12] Management Comments on Operating Environment and Future Outlook - Management highlighted a supportive environment for exploration investment and emphasized a strong cash flow generation and solid balance sheet [12] - The company is focused on achieving a stable 2,000 tons per day throughput at San Gabriel by Q3 2026 [11] Other Important Information - The board approved a dividend of $0.9904 per share, totaling $1.135 per share over the past 12 months [7] - The company received $98 million in dividends from its stake in Cerro Verde after the quarter ended [7] Q&A Session Summary Question: CapEx increase and reasons behind it - Management explained that the significant increase in CapEx is primarily due to pending works related to earthworks and ramp-up of the San Gabriel project [14][15] Question: Lower production guidance for San Gabriel - Management indicated that the lower guidance is due to the need for improved ventilation and a revised production plan following an accident [18][22] Question: Changes in mining plans due to rising metal prices - Management confirmed that only the San Gabriel mining plan has been reviewed, with no changes to copper and silver objectives [24] Question: G&A and exploration budget for 2026 - The expected G&A for 2026 is around $60 million-$70 million, with exploration budget increased to $90 million-$100 million [30] Question: Status of asset sales and potential decisions - Management is evaluating asset sales and will inform the market once a decision is made, considering the current precious metals prices [39][58]

Financial Data and Key Metrics Changes - For the full year 2025, net revenues were $719.9 million, with a modest decline of 2% year-over-year due to headwinds in legacy products [6][7] - Fourth quarter sales decreased 2% to $183.1 million from $186.5 million in the previous year, with net income reported at $24.4 million, or $0.51 per share, down from $38 million, or $0.74 per share in the prior year [11][14] - Adjusted net income for the fourth quarter was $34.2 million, or $0.73 per share, compared to $47.2 million, or $0.92 per share in the previous year [15] Business Line Data and Key Metrics Changes - BAQSIMI generated $185.4 million in revenue for the full year, up 12% year-over-year, while Primatene MIST sales rose 7% to $108.7 million [6][7] - In the fourth quarter, BAQSIMI sales grew 12% to $46.7 million, while Primatene MIST sales dropped 3% to $27.9 million [11][12] - Glucagon sales declined 45% to $14.1 million due to increased competition, and epinephrine sales decreased 9% to $17.1 million [12] Market Data and Key Metrics Changes - The company expects mid-single-digit unit growth for BAQSIMI in the U.S., offset by a planned reduction in international volume as it exits unprofitable markets [16][29] - The Atrovent market, associated with Ipratropium Bromide, was valued at $112 million last year, with expectations of meaningful market share due to 180 days of exclusivity [32] Company Strategy and Development Direction - The company aims to transition towards a portfolio anchored in high-value proprietary and biosimilar assets, with significant investments in R&D and manufacturing capabilities [5][9] - The expansion of the U.S. manufacturing facility in Rancho Cucamonga is a critical part of the long-term strategy, expected to quadruple production capacity [9][18] - The company plans to ramp up spending on clinical trials and materials for inhalation and proprietary pipeline products, with a focus on oncology, ophthalmology, and immunology [18][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of resilient commercial momentum and strategic pipeline progress, with expectations for consolidated revenue growth in the mid-to-high single-digit range for 2026 [20][17] - Gross margins are expected to be lower in 2026 due to pricing pressures on glucagon and epinephrine, alongside increased input costs [17][39] Other Important Information - The company has over $300 million in cash and short-term investments, with plans to utilize a portion for stock buybacks while also exploring business development opportunities [18][40] - The company achieved several major regulatory milestones in 2025, including FDA approvals for iron sucrose, teriparatide, and Ipratropium Bromide HFA [20][8] Q&A Session Summary Question: Development path for AMP-110 and business development priorities - Management has not yet engaged the FDA regarding AMP-110 but is preparing the program [24] - Business development will focus on areas where the company has or plans to have a presence, including endocrinology and oncology [25] Question: BAQSIMI expectations for 2026 and international sales - BAQSIMI is expected to see mid-single-digit growth in the U.S., with international sales declining in the second half of the year [29][30] Question: Gross margins and buyback plans - BAQSIMI growth will help margins, but declines in glucagon and epinephrine will offset this [39] - The company plans to continue buybacks, with $75 million as a potential high end for the year [40] Question: Competition for Primatene MIST and filing cadence - The patent for Primatene MIST has expired, but management does not anticipate significant competition [45] - The company expects to have 2 filings late this year and 2-3 filings next year [47] Question: Updates on Nanjing Anji in-licensed assets - The company is in the preclinical stage for these assets and is optimistic about their potential [50][51]

Acme United (NYSEAM:ACU) Q4 2025 Earnings call February 26, 2026 12:00 PM ET Speaker1Greetings. Welcome to the Acme United Q4 and Year-End 2025 Financial Results Conference Calling Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star 1 on your telephone keypad. As a reminder, this conference is being recorded. If anyone should require operator assistance, please ...

On innovation and demand activation, Fieldly said Celsius started 2026 with its Fizz-Free line available nationally , citing an opportunity to attract consumers seeking non-carbonated options. He said the company plans a more intentional cadence of innovation and limited-time offers (LTOs) in 2026, supported by broader distribution and in-market execution.Fieldly noted that the combined portfolio represented approximately one-fifth of the U.S. energy market in tracked channels for the full year, and said th ...

Essential Utilities (NYSE:WTRG) Q4 2025 Earnings call February 26, 2026 11:00 AM ET Company ParticipantsBrian Dingerdissen - VP of Financial Planning and Analysis, Treasury, and Investor RelationsChristopher Franklin - Chairman and CEODaniel Schuller - EVP and CFOConference Call ParticipantsPaul Zimbardo - Managing Director and Research AnalystTravis Miller - Senior Equity AnalystOperatorStanding by. My name is Jericho, and I'll be your conference operator today. At this time, I would like to welcome everyo ...

Service Properties Trust (NasdaqGS:SVC) Q4 2025 Earnings call February 26, 2026 10:00 AM ET Company ParticipantsBrian Donley - Treasurer and CFOChris Bilotto - President and CEOJesse Abair - VPKevin Barry - Senior Director of Investor RelationsConference Call ParticipantsJack Armstrong - Director and Senior Equity AnalystJohn Massocca - Senior Research AnalystTyler Batory - Executive Director and Senior AnalystOperatorGood morning, welcome to the Service Properties Trust Fourth Quarter 2025 Earnings Confere ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Vista Energy (NYSE:VIST) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsAlejandro Cherñacov - Strategic Planning and Investor Relations OfficerAlejandro Demichelis - Managing Director of LatAm Equity ResearchAndres Cardona - Director of LatAm Equity ResearchBruno Amorim - VP of Equity ResearchDaniel Guardiola - Executive Director of Equity ResearchKevin MacCurdy - Managing Director of Equity ResearchMiguel Galuccio - Founder, Chairman, and CEOWalter Chiaversio - Head of Equity Resea ...

Collegium Pharmaceutical (NasdaqGS:COLL) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorColleen Tupper - CFOIan Karp - Head of Investor RelationsJeevan Larson - Equity Research AssociateScott Dreyer - Chief Commercial OfficerVikram Karnani - President and CEOConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystOperatorGreetings! Welcome to the Collegium Pharmaceutical fourth quarter and full year 2025 earnings co ...

Nvidia Stock Pares Gains as Earnings Call ConcludesCONCLUDED[Nvidia Stock Pares Gains. It Had Another Big Earnings Beat.]Last Updated:---14 hours ago# Nvidia Stock Pares Gains as Earnings Call ConcludesBy[Adam Levine]As Nvidia concluded its fourth-quarter conference call, the stock was trading only modestly higher, up 0.6%.At one point in late trading, shortly after the report was released, the chip maker's stock was up 4%. ...